Mark Emberton MD, FRCS, OBE, FMedSci

Dr. Mark Emberton holds the post of Professor in Interventional Oncology at University College London. He is the Director, Division of Surgery and Interventional Science at UCL. He holds the position of Pathway Director for Urological Cancer for London Cancer—an integrated cancer system serving the residents of North London. He is also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In the area of prostate cancer, much of his activity is, at present, focused on evaluating minimally invasive therapies for localized disease. This work encompasses the precise characterization of disease as well as targeting therapies. He is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomized control trial in surgery. He is involved in guideline development and appraisal and is interested in the formulation of evidence-based management policies. He is an active researcher, has lectured widely, and has published over 200 peer-reviewed articles in numerous scientific journals.